University of Lorraine-ko ikertzaileekin lankidetzan egindako argitalpenak (23)

2024

  1. Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial

    Heart

2023

  1. Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study

    Circulation: Heart Failure, Vol. 16, Núm. 5, pp. E009694

  2. Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials

    International Journal of Cardiology, Vol. 377, pp. 86-88

2022

  1. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 2, pp. 321-331

  2. Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

    European Journal of Heart Failure, Vol. 24, Núm. 6, pp. 927-943

  3. Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

    European Journal of Heart Failure, Vol. 24, Núm. 6, pp. 944-958

  4. Dyskalemia in people at increased risk for heart failure: findings from the heart ‘OMics’ in AGEing (HOMAGE) trial

    ESC Heart Failure, Vol. 9, Núm. 6, pp. 4352-4357

  5. Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial

    European Journal of Heart Failure, Vol. 24, Núm. 5, pp. 771-778

  6. The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial

    European Journal of Heart Failure, Vol. 24, Núm. 9, pp. 1559-1568

2021

  1. Identification of sex-specific biomarkers predicting new-onset heart failure

    ESC Heart Failure, Vol. 8, Núm. 5, pp. 3512-3520

  2. Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF

    JACC: Heart Failure, Vol. 9, Núm. 4, pp. 268-277

  3. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: The heart 'OMics' in AGEing (HOMAGE) randomized clinical trial

    European Heart Journal, Vol. 42, Núm. 6, pp. 684-696

  4. Urinary peptides in heart failure: a link to molecular pathophysiology

    European Journal of Heart Failure, Vol. 23, Núm. 11, pp. 1875-1887

2020

  1. Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO-TARGETS case–control analyses

    Clinical Research in Cardiology, Vol. 109, Núm. 1, pp. 22-33

2019

  1. CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) axis in cardiac fibrosis and inflammation: Mechanistic insights and clinical implications

    Hypertension, Vol. 73, Núm. 3, pp. 602-611

  2. Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure

    Heart, Vol. 105, Núm. 4, pp. 307-314

  3. Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure: The HOMAGE Study

    Circulation: Heart Failure, Vol. 12, Núm. 5

2018

  1. Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis

    ESC Heart Failure, Vol. 5, Núm. 1, pp. 139-148

  2. Transitioning fromusual care to biomarkerbased personalized and precisionmedicine in heart failure: Call for action

    European Heart Journal, Vol. 39, Núm. 30, pp. 2793-2798

2017

  1. Myocardial fibrosis: biomedical research from bench to bedside

    European Journal of Heart Failure, Vol. 19, Núm. 2, pp. 177-191